Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Recommendation for Consideration for Licensure of Rotavirus Vaccine - Rotarix


Date: March 18, 2008

From: Inspectors: Pete Amin, CBER/OCBQ/DMPQ, HFM-676
Jonathan McInnis, CBER/OCBQ/DMPQ, HFM-676

Subject: Recommendation for consideration for licensure of Rotavirus Vaccine, STN 125265/0 is for manufacture, fill, and finishing at the -----------, Belgium, location.

To: Establishment Inspection File (EIF) for GlaxoSmith Kline Biologicals BLA File: STN BL 125265/0

We have reviewed and evaluated the January 15, 2008 responses from GSK Biologicals, which was in reply to the Form FDA-483 List of Observations dated December 13, 2007. The written statement of rationale to explain the observations noted during the pre-license inspection, appear to be adequate and complete. All corrective actions should be verified during the next routine GMP inspection of the firm.

Therefore, we recommend that the manufacture, fill and finishing sites in Buildings ----, ---- in ---------- and Building -- in Rixensart in ---------------, Belgium be approved as part of the license for Rotavirus Vaccine, STN 125265/0.

Pete Amin

Jonathan McInnis

Dino Feigelstock
Staff Fellow

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 09/18/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English